Report of Foreign Issuer (6-k)
September 02 2014 - 1:12PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of September 2014
Commission File Number 000-31062
Oncolytics Biotech Inc.
__________________________________
(Translation of registrant’s name into English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
__________________________________
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82 -
|
EXHIBIT
NUMBER
|
|
DESCRIPTION
|
| |
|
|
|
99.1
|
|
News Release Dated September 2, 2014 - Oncolytics Biotech® Inc. to Participate in the Baird 2014 Health Care Conference
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
|
|
|
|
| |
|
Oncolytics Biotech Inc.
(Registrant)
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
|
Date: September 2, 2014
|
|
By:
|
|
/s/ Kirk Look
Kirk Look
Chief Financial Officer
|
210, 1167 Kensington Cr. N.W.
Calgary, Alberta
Canada T2N 1X7
MEDIA ADVISORY
Oncolytics Biotech® Inc. to Participate in the Baird 2014 Health Care Conference
CALGARY, AB, September 2, 2014 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the Baird 2014 Health Care Conference in a session on Wednesday September 3rd, 2014 at 9:05 a.m. ET. The conference takes place on September 3rd and 4th at the New York Palace, in New York, NY.
A live audio link to the webcast session will be available at: http://wsw.com/webcast/baird39/oncy or on the company’s website at http://www.oncolyticsbiotech.com/for-investors/presentations. It is recommended that listeners log on 10 minutes in advance of a live session to register and download any necessary software. An audio replay will be accessible approximately two hours following the presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
The session and webcast times are subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company’s control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.
FOR FURTHER INFORMATION PLEASE CONTACT:
|
TMX Equicom
Nick Hurst
300 5th Ave. SW, 10th Floor
Calgary, Alberta T2P 3C4
Tel: 403.218.2835
Fax: 403.218.2830
nhurst@tmxequicom.com
|
TMX Equicom
Michael Moore
San Diego, CA 92109
Tel: 858.886.7813
mmoore@tmxequicom.com
|
Dian Griesel, Inc.
Susan Forman
335 West 38th Street, 3rd Floor
New York, NY 10018
Tel: 212.825.3210
Fax: 212.825.3229
sforman@dgicomm.com
|
-30-